{Reference Type}: Case Reports
{Title}: REVERSIBLE NEUROTROPHIC KERATOPATHY ASSOCIATED WITH ROSUVASTATIN THERAPY: A CASE REPORT.
{Author}: Elnahry AG;Elnahry GA;
{Journal}: J Popul Ther Clin Pharmacol
{Volume}: 26
{Issue}: 2
{Year}: 08 2019 16
暂无{DOI}: 10.15586/jptcp.v26i2.627
{Abstract}: Rosuvastatin is a 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme inhibitor that is in wide use with few reported ocular adverse events.<BR>To report a case of bilateral neurotrophic keratopathy associated with rosuvastatin therapy that dramatically improved following drug discontinuation.<BR>A 65-year-old female presented with painless diminution of vision in both eyes of gradual onset and progressive course for 1 month. She had recently started rosuvastatin therapy for hyperlipidemia. Examination revealed bilateral stage 2 neurotrophic keratopathy with impaired corneal sensation which was previously resistant to conservative ulcer treatment. Following discontinuation of rosuvastatin therapy, there was dramatic bilateral improvement in corneal sensation, size of the corneal ulcers, and visual acuity.<BR>Rosuvastatin may result in reversible trigeminal nerve impairment and neurotrophic keratopathy.